{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:21:41Z","timestamp":1783606901870,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12200-3","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:43:13Z","timestamp":1783604593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tankyrase inhibition restores chemosensitivity in triple-negative breast cancer cells by disrupting TFEB\/\u03b2-Catenin\/ABCG2 axis"],"prefix":"10.1007","volume":"53","author":[{"given":"Shariqa","family":"Jan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaneez","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayaz A.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"12200_CR1","first-page":"681476","volume":"11","author":"M Ensenyat-Mendez","year":"2021","unstructured":"Ensenyat-Mendez M et al (2021) Curr triple-negative breast cancer subtypes: dissecting most aggressive form breast cancer 11:681476","journal-title":"Curr triple-negative breast cancer subtypes: dissecting most aggressive form breast cancer"},{"key":"12200_CR2","doi-asserted-by":"crossref","unstructured":"Kim HJ et al (2022) The impact of young age at diagnosis (age\u2009<\u200940 years) on prognosis varies by breast cancer subtype: A US SEER database analysis. 61: pp. 77\u201383","DOI":"10.1016\/j.breast.2021.12.006"},{"issue":"2","key":"12200_CR3","first-page":"247","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P (2016) R.J.A.o.g. Aggarwal, and obstetrics. Overv triple-negative breast cancer 293(2):247\u2013269","journal-title":"Overv triple-negative breast cancer"},{"key":"12200_CR4","doi-asserted-by":"crossref","unstructured":"Thanopoulou E et al (2020) Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+\/HER2+) breast cancer: a review of the current literature. 12(11):3317","DOI":"10.3390\/cancers12113317"},{"key":"12200_CR5","doi-asserted-by":"crossref","unstructured":"Roskoski RJPR Jr (2024) Targeted and cytotoxic inhibitors used in the treatment of breast cancer. : p. 107534","DOI":"10.1016\/j.phrs.2024.107534"},{"issue":"1","key":"12200_CR6","first-page":"109","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU et al (2024) Unveiling Mech challenges cancer drug Resist 22(1):109","journal-title":"Unveiling Mech challenges cancer drug Resist"},{"key":"12200_CR7","doi-asserted-by":"crossref","unstructured":"Poggio F et al (2018) Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. 29(7):1497\u20131508","DOI":"10.1093\/annonc\/mdy127"},{"issue":"2","key":"12200_CR8","first-page":"148","volume":"53","author":"TJR Makovec","year":"2019","unstructured":"Makovec TJR, oncology (2019) Cisplatin beyond: Mol Mech action drug Resist Dev cancer Chemother 53(2):148","journal-title":"Cisplatin beyond: Mol Mech action drug Resist Dev cancer Chemother"},{"key":"12200_CR9","doi-asserted-by":"crossref","unstructured":"Gupte R et al (2017) PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. 31(2):101\u2013126","DOI":"10.1101\/gad.291518.116"},{"key":"12200_CR10","doi-asserted-by":"crossref","unstructured":"Poltronieri P et al (2021) NAD precursors, mitochondria targeting compounds and ADP-ribosylation inhibitors in treatment of inflammatory diseases and cancer. 28(41):8453\u20138479","DOI":"10.2174\/0929867328666210118152653"},{"issue":"3","key":"12200_CR11","first-page":"131","volume":"14","author":"H Wei","year":"2016","unstructured":"Wei H (2016) Yu, proteomics, and bioinformatics. Funct PARylation DNA damage repair pathways 14(3):131\u2013139","journal-title":"Funct PARylation DNA damage repair pathways"},{"key":"12200_CR12","doi-asserted-by":"crossref","unstructured":"Vijaya Lakshmi T et al (2017) Tankyrase as a novel molecular target in cancer and fibrotic diseases. 18(10):1214\u20131224","DOI":"10.2174\/1389450117666160715152503"},{"key":"12200_CR13","doi-asserted-by":"crossref","unstructured":"Mariotti L, Pollock K, J.B.J.o S (2017) Regulation of Wnt\/\u03b2-catenin signalling by tankyrase\u2010dependent poly (ADP\u2010ribosyl) ation and scaffolding. 174(24): pp. 4611\u20134636","DOI":"10.1111\/bph.14038"},{"key":"12200_CR14","doi-asserted-by":"crossref","unstructured":"Haikarainen T, Krauss S (2014) and L.J.C.p.d. Lehtio, Tankyrases: structure, function and therapeutic implications in cancer. 20(41): pp. 6472\u20136488","DOI":"10.2174\/1381612820666140630101525"},{"key":"12200_CR15","doi-asserted-by":"crossref","unstructured":"Verma A et al (2021) Tankyrase inhibitors: emerging and promising therapeutics for cancer treatment. 30(1):50\u201373","DOI":"10.1007\/s00044-020-02657-7"},{"key":"12200_CR16","doi-asserted-by":"crossref","unstructured":"Casas-Selves M et al (2012) Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. 72(16):4154\u20134164","DOI":"10.1158\/0008-5472.CAN-11-2848"},{"issue":"4","key":"12200_CR17","first-page":"1333","volume":"48","author":"X Wu","year":"2016","unstructured":"Wu X et al (2016) Tankyrase 1 inhibitior XAV939 increases chemosensitivity. colon cancer cell lines via Inhib Wnt Signal Pathw 48(4):1333\u20131340","journal-title":"colon cancer cell lines via Inhib Wnt Signal Pathw"},{"key":"12200_CR18","doi-asserted-by":"crossref","unstructured":"Franco-Ju\u00e1rez B et al (2022) TFEB; beyond its role as an autophagy and lysosomes regulator. 11(19):3153","DOI":"10.3390\/cells11193153"},{"key":"12200_CR19","doi-asserted-by":"crossref","unstructured":"Kim S et al (2021) PARsylated transcription factor EB (TFEB) regulates the expression of a subset of Wnt target genes by forming a complex with \u03b2-catenin-TCF\/LEF1. 28(9):2555\u20132570","DOI":"10.1038\/s41418-021-00770-7"},{"key":"12200_CR20","doi-asserted-by":"crossref","unstructured":"Li S et al (2020) Wnt\/\u03b2-catenin signaling axis is required for TFEB-mediated gastric cancer metastasis and epithelial\u2013mesenchymal transition. 18(11):1650\u20131659","DOI":"10.1158\/1541-7786.MCR-20-0180"},{"issue":"2","key":"12200_CR21","first-page":"1883","volume":"48","author":"P-DM Juan-Carlos","year":"2021","unstructured":"Juan-Carlos P-DM et al (2021) ABC transporter superfamily. An updated overview. relevance cancer multidrug Resist Perspect personalized Med 48(2):1883\u20131901","journal-title":"relevance cancer multidrug Resist Perspect personalized Med"},{"issue":"11","key":"12200_CR22","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3390\/ijms18112362","volume":"18","author":"R-R Begicevic","year":"2017","unstructured":"Begicevic R-R, Falasca M (2017) ABC transporters in cancer stem cells: beyond chemoresistance. Int J Mol Sci 18(11):2362","journal-title":"Int J Mol Sci"},{"issue":"W1","key":"12200_CR23","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z et al (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98\u2013W102","journal-title":"Nucleic Acids Res"},{"issue":"W1","key":"12200_CR24","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T et al (2020) TIMER2. 0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 48(W1):W509\u2013W514","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"12200_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12032-023-01963-5","volume":"40","author":"SU Khan","year":"2023","unstructured":"Khan SU et al (2023) Small molecule \u20184ab\u2019induced autophagy and endoplasmic reticulum stress-mediated death of aggressive cancer cells grown under adherent and floating conditions. Med Oncol 40(4):121","journal-title":"Med Oncol"},{"key":"12200_CR26","doi-asserted-by":"crossref","unstructured":"Roy S et al (2019) Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells. 846:503084","DOI":"10.1016\/j.mrgentox.2019.503084"},{"key":"12200_CR27","doi-asserted-by":"crossref","unstructured":"Ismail J et al (2025) Combination of Cannabidiol with Cisplatin or Paclitaxel Analysis Using the Chou\u2013Talalay Method and Chemo-Sensitization Evaluation in Platinum-Resistant Ovarian Cancer Cells. 13(2):520","DOI":"10.3390\/biomedicines13020520"},{"issue":"1","key":"12200_CR28","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1038\/s41598-022-07955-1","volume":"12","author":"SU Khan","year":"2022","unstructured":"Khan SU et al (2022) Activation of lysosomal mediated cell death in the course of autophagy by mTORC1 inhibitor. Sci Rep 12(1):5052","journal-title":"Sci Rep"},{"key":"12200_CR29","doi-asserted-by":"crossref","unstructured":"Zhang Y et al (2011) RNF146 is a poly (ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. 13(5):623\u2013629","DOI":"10.1038\/ncb2222"},{"issue":"7264","key":"12200_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nature08356","volume":"461","author":"S-MA Huang","year":"2009","unstructured":"Huang S-MA et al (2009) Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461(7264):614\u2013620","journal-title":"Nature"},{"issue":"8","key":"12200_CR31","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.bcp.2012.01.002","volume":"83","author":"K Natarajan","year":"2012","unstructured":"Natarajan K et al (2012) Role of breast cancer resistance protein (BCRP\/ABCG2) in cancer drug resistance. Biochem Pharmacol 83(8):1084\u20131103","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"12200_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cbf.3577","volume":"39","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer. Cell Biochem Funct 39(2):277\u2013286","journal-title":"Cell Biochem Funct"},{"issue":"4","key":"12200_CR33","first-page":"5155","volume":"15","author":"W Zhang","year":"2018","unstructured":"Zhang W et al (2018) Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway. Oncol Lett 15(4):5155\u20135160","journal-title":"Oncol Lett"},{"issue":"6","key":"12200_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/2211-5463.12220","volume":"7","author":"MY Xia","year":"2017","unstructured":"Xia MY et al (2017) Activation of Wnt\/\u03b2-catenin signaling by lithium chloride attenuates d\u2010galactose\u2010induced neurodegeneration in the auditory cortex of a rat model of aging. FEBS open bio 7(6):759\u2013776","journal-title":"FEBS open bio"},{"key":"12200_CR35","doi-asserted-by":"crossref","unstructured":"Kinnel B et al (2023) Targeted therapy and mechanisms of drug resistance in breast cancer. 15(4):1320","DOI":"10.3390\/cancers15041320"},{"key":"12200_CR36","doi-asserted-by":"crossref","unstructured":"Ha G et al (2012) Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation. 19(2): pp. 321\u2013332","DOI":"10.1038\/cdd.2011.101"},{"issue":"7264","key":"12200_CR37","first-page":"614","volume":"461","author":"S-MA Huang","year":"2009","unstructured":"Huang S-MA et al (2009) Tankyrase Inhib stabilizes axin antagonizes Wnt Signal 461(7264):614\u2013620","journal-title":"Tankyrase Inhib stabilizes axin antagonizes Wnt Signal"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12200-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:43:17Z","timestamp":1783604597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12200-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12200"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12200-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"4 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In this study, the utilisation of experimental animals received approval from the Ethics and Institutional Animal Care and Use Committees of the Council of Scientific and Industrial Research-Indian Institute of Integrative Medicine (CSIR-IIIM), in accordance with the guidelines established by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). I confirm that all procedures were conducted in accordance with applicable rules and regulations. I confirm that the research was executed in compliance with the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of ethics and consent for participation"}}],"article-number":"1123"}}